Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scherzer

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Archives of Neurology|June 16, 2005
Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonismMichael A Hauser, Yi-Ju Li, Hong Xu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 2, 2022
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based StudyAleksandra A Szwedo, Ingvild Dalen, Kenn Freddy Pedersen, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Single cell eQTL mapping reveals convergent glial-neuronal risk architecture in Parkinson's diseaseZechuan Lin, Jacob Parker, Vanitha Nithianandam, et al.
BMJ Open|February 26, 2022
Australian Parkinson's Genetics Study (APGS): pilot (n=1532)Svetlana Bivol, George D Mellick, Jacob Gratten, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2021
Accelerating Medicines Partnership: Parkinson's Disease. Genetic ResourceHirotaka Iwaki, Hampton L Leonard, Mary B Makarious, et al.
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Nature Neuroscience|November 29, 2018
Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric diseaseXianjun Dong, Zhixiang Liao, David Gritsch, et al.
Nature Neuroscience|September 19, 2018
Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric diseaseXianjun Dong, Zhixiang Liao, David Gritsch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 3, 2025
Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's DiseaseYu Liao, Hao Wu, Junhao Wang, et al.
Neurology|January 29, 2026
Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related DementiasPia Kivisäkk, Hadia Fatima, Chao-Yi Wu, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Archives of Neurology|June 16, 2005
Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonismMichael A Hauser, Yi-Ju Li, Hong Xu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 2, 2022
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based StudyAleksandra A Szwedo, Ingvild Dalen, Kenn Freddy Pedersen, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Single cell eQTL mapping reveals convergent glial-neuronal risk architecture in Parkinson's diseaseZechuan Lin, Jacob Parker, Vanitha Nithianandam, et al.
BMJ Open|February 26, 2022
Australian Parkinson's Genetics Study (APGS): pilot (n=1532)Svetlana Bivol, George D Mellick, Jacob Gratten, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2021
Accelerating Medicines Partnership: Parkinson's Disease. Genetic ResourceHirotaka Iwaki, Hampton L Leonard, Mary B Makarious, et al.
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
Nature Neuroscience|November 29, 2018
Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric diseaseXianjun Dong, Zhixiang Liao, David Gritsch, et al.
Nature Neuroscience|September 19, 2018
Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric diseaseXianjun Dong, Zhixiang Liao, David Gritsch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 3, 2025
Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's DiseaseYu Liao, Hao Wu, Junhao Wang, et al.
Neurology|January 29, 2026
Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related DementiasPia Kivisäkk, Hadia Fatima, Chao-Yi Wu, et al.
Pageof 14